Baxter International Inc. has initiated a phase III pivotal clinical trial to evaluate the use of adult autologous (an individual's own) stem cells to increase exercise capacity in patients who suffer from chronic myocardial ischemia (CMI), a disease that results in reduced blood supply to the heart that can lead to long-term tissue damage and heart failure.
StemSave Blog
Baxter International Initiates Phase III Autologous Stem Cell Clinical Trial to Improve Patients with CMI
Posted by taylor@stemsave.com on Mar 30, 2012 3:28:02 PM
0 Comments Click here to read/write comments
Topics: CMI, stemsaveblog, chronic myocardial ischemia, Baxter International Inc, Baxter International